Sarah Yuan

Sarah Yuan, Ph.D., brings more than 20 years of experience in process development, manufacturing sciences, and CMC strategies from a broad range of leading biopharmaceutical companies. Prior to joining Sigilon Therapeutics, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio. At 2seventy bio, she was instrumental in getting three cell therapy products approved, in addition to advancing a preclinical product through IND clearance. Previously, Dr. Yuan led the External Manufacturing Organization for the Rare Blood Disorders Franchise at Sanofi. She also served as the Head of Technical Development and Manufacturing Sciences at Bioverativ, prior to its acquisition by Sanofi. At Bioverativ, she built and developed high-functioning teams responsible for overseeing external manufacturing operations, developing and executing CMC strategies, delivering manufacturing processes, and analytical methods, and driving life cycle management initiatives for all clinical and commercial products.